百亿基金经理收益回暖！张坤规模领衔，王明旭7产品年内亏损

Group 1 - The core viewpoint of the articles indicates a strong recovery in the performance of actively managed equity funds in 2025, with 95% of these funds achieving positive returns and an average return exceeding 15% as of August 7 [2][3] - The pharmaceutical sector has emerged as the biggest winner, with four actively managed equity funds achieving returns that have doubled this year, all focusing on the pharmaceutical industry [4][5] - As of mid-2025, there are 90 fund managers managing over 10 billion yuan, with Zhang Kun from E Fund leading with over 50 billion yuan under management [8][9] Group 2 - The average return of actively managed equity funds has outperformed major stock indices, such as the CSI 300 and the CSI 500, which recorded returns of 4.6% and 10.6% respectively [3] - The average return of the entire market of over 4,500 actively managed equity funds is 15.03%, compared to 11.8% for over 2,500 stock index funds [3] - Despite the overall positive performance, there are still 228 actively managed equity funds with negative returns, with the worst performer, Qianhai Kaiyuan AI A, showing a return of -18.5% [4][6] Group 3 - The top-performing funds in the pharmaceutical sector include Changcheng Pharmaceutical Industry Selection, Bank of China Hong Kong Stock Connect Pharmaceutical, Yongying Pharmaceutical Innovation Selection, and Huashan Pharmaceutical Biotechnology, all achieving significant returns [4][5] - The performance of fund managers varies significantly, with some, like Zhang Wei and Zhang Lu, achieving returns of 65.8% and 53.4% respectively, while others, such as Wang Mingxu, have negative returns [12][13] - The total scale of actively managed equity funds reached 3.39 trillion yuan by mid-2025, although the total number of shares decreased by 198.24 billion compared to the end of the previous year [6][7]